Myriad Genetics INC Form 4 insider transactions

NASDAQ
Myriad Genetics' Chief Operating Officer, Mark Verratti, disposed of 2,055 shares of common stock to cover tax withholding obligations related to vested restricted stock units.
NASDAQ
MYRIAD GENETICS CFO Benjamin Wheeler reported a disposition of 549 common shares to cover tax obligations from vested restricted stock units.
NASDAQ
Myriad Genetics' Chief Technology Officer, Kevin Richard Haas, has departed the company and reported the disposition of shares related to tax withholdings from vested restricted stock units.
NASDAQ
Myriad Genetics' Chief People Officer, Shereen Solaiman, reported the acquisition of 173,196 restricted stock units and subsequent dispositions for tax withholding.
NASDAQ
Myriad Genetics Chief Scientific Officer Dale Muzzey reported the vesting of restricted stock units and subsequent share disposals for tax obligations.
NASDAQ
Myriad Genetics' Chief Legal Officer, Jennifer Lynne Fox, received a significant grant of restricted stock units and had shares withheld for tax obligations.
NASDAQ
Myriad Genetics' Chief Commercial Officer, Brian J. Donnelly, was granted 226,804 restricted stock units, increasing his beneficial ownership to 624,338 shares.
NASDAQ
Myriad Genetics COO Mark Verratti reported the grant of 247,423 restricted stock units and subsequent tax-related share disposals.
NASDAQ
Myriad Genetics CFO Benjamin Richard Wheeler reported the acquisition of 206,186 restricted stock units and subsequent disposals for tax withholding.
NASDAQ
Myriad Genetics CEO Samraat Raha reported the acquisition of 618,557 restricted stock units and subsequent tax-related dispositions.
NASDAQ
Myriad Genetics Director S. Louise Phanstiel acquired over 100,000 shares of common stock in open market purchases, increasing her direct beneficial ownership.
NASDAQ
Myriad Genetics' Chief Financial Officer, Benjamin Richard Wheeler, acquired 4,994 shares of common stock through a performance-based restricted stock unit award.
NASDAQ
Myriad Genetics Chief Operating Officer Mark Verratti acquired 32,810 shares of common stock through the vesting of performance-based restricted stock units.
NASDAQ
Myriad Genetics' Chief Scientific Officer, Dale Muzzey, was awarded 23,697 shares of common stock following the achievement of performance metrics for previously granted restricted stock units.
NASDAQ
Myriad Genetics' Chief Technology Officer, Kevin Richard Haas, was awarded 23,697 shares of common stock following the achievement of performance metrics for previously granted restricted stock units.
NASDAQ
Myriad Genetics Chief Scientific Officer Dale Muzzey disposed of 418 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.
NASDAQ
Myriad Genetics CFO Benjamin Wheeler disposed of 21 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.
NASDAQ
Myriad Genetics Inc. CEO Samraat S. Raha disposed of 29,634 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.
NASDAQ
Margaret Ancona, EVP of Strategy & Transformation at Myriad Genetics, will cease her role effective November 3, 2025, as reported in a recent Form 4 filing.
NASDAQ
Natalie Munk, Chief Accounting Officer of Myriad Genetics Inc., has ceased her role and is no longer subject to Section 16 reporting requirements as of October 24, 2025.
NASDAQ
Myriad Genetics Chief Operating Officer Mark Verratti disposed of 1,085 shares of common stock to cover tax obligations related to restricted stock unit vesting.
NASDAQ
Myriad Genetics' Chief Accounting Officer, Natalie Munk, reported the disposition of 962 shares for tax withholding related to restricted stock unit vesting.
NASDAQ
Myriad Genetics' Chief Financial Officer, Benjamin Richard Wheeler, disposed of 2,559 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.
NASDAQ
Myriad Genetics EVP Margaret Ancona reported the withholding of 958 shares of common stock to cover tax obligations related to vested restricted stock units.
NASDAQ
Myriad Genetics' Chief Legal Officer, Jennifer Lynne Fox, disposed of 4,435 shares of common stock to cover tax obligations related to restricted stock unit vesting.
NASDAQ
Myriad Genetics' Chief Financial Officer, Benjamin Richard Wheeler, was granted 60,000 restricted stock units, increasing his beneficial ownership to 95,210 shares.
NASDAQ
Myriad Genetics Inc. reports the departure of Chief Financial Officer Scott J. Leffler, effective August 15, 2025, as disclosed in a Form 4 filing.
NASDAQ
Myriad Genetics Inc. Director Heinrich Dreismann has increased his beneficial ownership by 49,796 shares of common stock through a restricted stock unit grant, bringing his total holdings to 171,444 shares.
NASDAQ
Myriad Genetics Inc. Director Paul Bisaro was granted 49,796 restricted stock units, increasing his beneficial ownership to 89,941 shares, aligning his interests with shareholders.
NASDAQ
Myriad Genetics Inc. Director S. Louise Phanstiel reported the acquisition of 49,796 shares of common stock through a restricted stock unit grant on June 5, 2025, increasing her total beneficial ownership to 177,444 shares.